Quality in Sport. 2026;51:68504. eISSN 2450-3118.

https://doi.org/10.12775/QS.2026.51.68504



Quality in Sport. eISSN 2450-3118

Journal Home Page
https://apcz.umk.pl/QS/index

BULLMANN, Agnieszka Irena, BARAN, Julia, WOJCIECHOWSKA, Karolina, CHOROSZEWSKA, Ewelina, WARYCH, Wiktor, NIEZGODA, Julia, SKŁODOWSKI, Tomasz and WORONIECKA, Katarzyna. The Role of Myo-Inositol in the Management of Metabolic and Reproductive Sequelae of Polycystic Ovary Syndrome: A Comprehensive Review of the Current State of Knowledge. Quality in Sport. 2026;51:68504. eISSN 2450-3118. https://doi.org/10.12775/QS.2026.51.68504

The journal has been awarded 20 points in the parametric evaluation by the Ministry of Higher Education and Science of Poland. This is according to the Annex to the announcement of the Minister of Higher Education and Science dated 05.01.2024, No. 32553. The journal has a Unique Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).
The authors declare that there is no conflict of interest regarding the publication of this paper.
Received: 22.01.2026. Revised: 01.02.2026. Accepted: 01.02.2026. Published: 10.02.2026.

The Role of Myo-Inositol in the Management of Metabolic and Reproductive Sequelae of Polycystic Ovary Syndrome: A Comprehensive Review of the Current State of Knowledge

Agnieszka Bullmann[1] [AB], ORCID https://orcid.org/0009-0001-4338-3027

E-mail: agabullmann00@gmail.com

Julia Baran[2] [JB], ORCID https://orcid.org/0009-0005-9569-3149

E-mail: barjul99@gmail.com

Karolina Wojciechowska[3] [KW], ORCID https://orcid.org/0009-0001-7048-1335
E-mail: karolina8wojciechowska@gmail.com

Ewelina Choroszewska[3] [EC], ORCID https://orcid.org/0009-0000-7609-7265
E-mail: choroszewska2000@gmail.com

Wiktor Warych[3] [WW], ORCID https://orcid.org/0009-0003-2569-6833
E-mail: w.warych26@gmail.com

Julia Niezgoda[4] [JN], ORCID https://orcid.org/0009-0000-4890-8323
E-mail: niezgodajulia001@gmail.com

Tomasz Skłodowski[4] [TS], ORCID https://orcid.org/0009-0000-4250-1485
E-mail: cele1303@wp.pl

Katarzyna Woroniecka[4] [KW[2]], ORCID https://orcid.org/0009-0004-3203-8609
E-mail: kasiaworonieckaa@gmail.com

[1] Szpital Specjalistyczny im. F. Ceynowy, ul. dr. Alojzego Jagalskiego 10, 84-200 Wejherowo, Poland

[2] University Clinical Hospital in Białystok, ul. M. C. Skłodowskiej 24a, 15-276 Białystok, Poland

[3] Śniadeckiego Voivodeship Hospital in Bialystok, ul. M. C. Skłodowskiej 26, 15-278 Białystok, Poland

[4]Medical University of Białystok, ul. Jana Kilińskiego 1, 15-089 Białystok, Poland

Corresponding Author: Agnieszka Bullmann, agabullmann00@gmail.com

Abstract

Polycystic Ovary Syndrome (PCOS) represents a heterogeneous and multifaceted endocrinopathy, characterized by extensive metabolic implications, affecting a substantial global cohort of reproductive-age women. Central to its pathogenesis is insulin resistance (IR) and compensatory hyperinsulinemia, which drive both metabolic dysfunction and reproductive failures. Myo-inositol (MI), acting as a vital second messenger for both insulin and follicle-stimulating hormone (FSH), has emerged as a cornerstone therapeutic agent. This comprehensive review evaluates the clinical efficacy of MI, particularly when administered in the physiological 40:1 ratio with D-chiro-inositol (DCI). We analyze its impact on glycemic profiles, hormonal stabilization, and the enhancement of oocyte competence. Based on the 2023 International Evidence-based Guidelines and recent clinical trials, MI represents a safe, well-tolerated, and effective alternative to traditional pharmacological interventions, providing a holistic approach to PCOS management.

Background and Pathophysiology: Polycystic Ovary Syndrome is the most frequent endocrinopathy affecting women, with prevalence rates estimated between 8% and 13% depending on the diagnostic criteria. Beyond the classic symptoms of oligo-anovulation and hyperandrogenism, the syndrome is inextricably linked to systemic metabolic challenges, including dyslipidemia, obesity, and an increased risk of type 2 diabetes and cardiovascular disease.

The discovery of the "Ovarian Paradox" has revolutionized our understanding of PCOS. While peripheral tissues in PCOS patients exhibit significant resistance to insulin, the ovaries remain sensitive. This leads to an over-activation of the epimerase enzyme, which converts myo-inositol into D-chiro-inositol within the ovarian follicles. The resulting localized deficiency of myo-inositol impairs FSH signaling, which is essential for follicular maturation, leading to the arrest of follicle development and poor oocyte quality. Restoring the intra-ovarian milieu through exogenous MI supplementation is therefore a targeted physiological necessity rather than a mere dietary intervention.

Aim of the Study: The primary objective of this comprehensive review is to synthesize the latest scientific evidence regarding the use of myo-inositol in managing the multifaceted consequences of PCOS. This work focuses on evaluating the clinical effectiveness of MI in restoring regular ovulatory cycles and correcting the metabolic disturbances associated with the syndrome. A significant portion of this analysis is dedicated to investigating how MI improves

oocyte quality and embryo development, which are critical for patients undergoing assisted reproductive technologies (ART). Furthermore, we aim to clarify the clinical superiority of the 40:1 MI:DCI ratio compared to other inositol formulations. By examining 21 key publications, this review seeks to provide clinicians with an evidence-based framework for incorporating inositol therapy into standard PCOS care. We also explore the safety profile and patient compliance associated with long-term myo-inositol supplementation.

Materials and Methods: A systematic review was conducted based on 21 scientific publications, including the 2023 International Evidence-based Guidelines, network meta-analyses, and recent prospective clinical trials. The search focused on studies evaluating myo-inositol's impact on insulin sensitivity, hormonal balance, and reproductive outcomes across various PCOS phenotypes, including adolescent populations and the use of co-factors like alpha-lactalbumin

Results: Clinical data indicate that 4g/day of MI significantly reduces fasting insulin and HOMA-IR, offering metabolic benefits comparable to Metformin but with superior tolerability. In terms of reproduction, 70-80% of patients restored regular cycles within 3-6 months. In ART cycles, MI supplementation reduced FSH requirements, lowered the risk of OHSS, and improved oocyte quality (MII) and embryo grading. The 40:1 ratio was confirmed as the most effective for restoring the intra-ovarian milieu. In adolescents, MI restored cycles in over 80% of cases.

Conclusions: Myo-inositol, particularly in the physiological 40:1 ratio, represents a safe and effective first-line intervention for PCOS, matching the efficacy of Metformin with superior tolerability. Its role in enhancing oocyte quality and reducing OHSS risk makes it a cornerstone of modern ART protocols. Furthermore, the incorporation of alpha-lactalbumin provides a breakthrough for inositol-resistant patients by increasing bioavailability. Given its high compliance and safety in adolescents, MI should be integrated into long-term management standards for PCOS.

Keywords: PCOS, Myo-inositol, Insulin Resistance, Oocyte Quality, Hyperandrogenism, 40:1 MI:DCI Ratio.

Content

1. Introduction

PCOS is traditionally characterized by a triad of symptoms: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology (PCOM). Contemporary research indicates that the underlying cause of these diverse symptoms is a fundamental defect in the insulin signaling pathway. Inositols, which are naturally occurring sugar alcohols, function as vital intracellular messengers that relay signals from insulin and gonadotropin receptors. Myo-inositol (MI) is specifically responsible for glucose uptake and the mediation of FSH signals, whereas D-chiro-inositol (DCI) facilitates glycogen synthesis and regulates androgen production. In a healthy physiological state, the ratio of MI to DCI in the ovaries is strictly maintained at a high level to ensure proper follicular maturation. However, in women

with PCOS, this ratio is severely disrupted due to altered epimerase activity, leading to a state of "ovarian inositol depletion." This imbalance creates a toxic environment for the developing egg and exacerbates the hormonal chaos seen in the syndrome.

2. Materials and Methods

To ensure a robust and comprehensive analysis, a systematic literature review was conducted focusing on the therapeutic role of myo-inositol in Polycystic Ovary Syndrome. The search was performed using primary electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar. The selection process was based on a curated set of 21 key scientific publications, with particular emphasis on the 2023 International Evidence-based Guideline for the assessment and management of PCOS (International Evidence-based Guideline, 2023).

The methodology involved a detailed examination of diverse study designs, including network meta-analyses (Zhao et al., 2021) and recent prospective clinical trials (Pustotina et al., 2024; Sharon et al., 2024). Studies were screened for their relevance to core PCOS indicators: insulin sensitivity, hormonal stabilization, and reproductive outcomes such as oocyte quality and embryo development. A comparative analysis was specifically performed between myo-inositol and metformin to evaluate relative clinical efficacy and safety profiles (Szkodziak & Paszkowski, 2016).

Furthermore, the review incorporated specialized research addressing the unique clinical needs of adolescent populations (Radomski & Jarząbek-Bielecka, 2019). The analysis also extended to the synergistic effects of co-factors, including alpha-lactalbumin, vitamin D3, and melatonin, by synthesizing data from recent international and Polish clinical studies (Oszukowski & Jakimiuk, 2014; Wdowiak, 2016). The inclusion criteria focused on papers published or updated within the last five years to ensure the integration of the most current medical evidence.

3. Research Results

3.1. Metabolic Stabilization and Glycemic Profile

Clinical data consistently demonstrate that myo-inositol supplementation at a dosage of 4g per day leads to a significant reduction in fasting insulin levels and the HOMA-IR index. In overweight and obese patients, MI acts as a pharmacological catalyst that, when combined with lifestyle modifications, facilitates weight loss and reduces the Waist-to-Hip Ratio (WHR). Furthermore, MI shows a positive impact on the lipid profile by decreasing total cholesterol and LDL levels while increasing HDL concentrations. Compared to Metformin, MI provides

comparable metabolic benefits but with a significantly superior safety profile, as it lacks the gastrointestinal distress (nausea, diarrhea) that often leads to high dropout rates in Metformin therapy.

3.2. Reproductive Outcomes and Oocyte Quality

The restoration of regular menstrual cycles is observed in approximately 70-80% of women within 3 to 6 months of MI therapy. MI acts directly within the follicular fluid, where its concentration serves as a marker of oocyte quality. In patients undergoing Assisted Reproductive Technology (ART), MI pretreatment reduces the total dose of recombinant FSH required for stimulation and shortens the stimulation period. This reduction is critical as it significantly lowers the risk of Ovarian Hyperstimulation Syndrome (OHSS). Clinical trials report an increased number of retrieved mature (MII) oocytes and a higher percentage of top-quality embryos, leading to improved clinical pregnancy rates.

3.3. The 40:1 MI:DCI Ratio: The Gold Standard

The synthesis of current evidence confirms that the 40:1 MI:DCI ratio is the most effective formulation for PCOS. This ratio mirrors the physiological concentration found in human plasma. While low doses of DCI can assist in systemic glucose metabolism, high doses of DCI are detrimental to the ovaries, as they can inhibit aromatase and further increase androgen levels. The 40:1 combination provides the necessary MI for FSH signaling while providing enough DCI to aid peripheral insulin sensitivity, thus avoiding the negative consequences of DCI monotherapy or incorrect ratios.

3.4. Adolescent Populations and Early Intervention

Managing PCOS in adolescents requires a cautious approach. Research indicates that early intervention with MI in girls with oligomenorrhea and signs of hyperandrogenism (such as acne) can restore regular cycles in over 80% of cases. MI represents a safe alternative to oral contraceptive pills (OCPs) in this age group, as it addresses the underlying insulin resistance rather than merely masking hormonal symptoms. This early stabilization is crucial for preventing long-term metabolic complications.

4. Discussion

4.1. Metabolic Implications and the Shift in Therapeutic Paradigms

The results of this review underscore a significant shift in the management of Polycystic Ovary Syndrome (PCOS), moving from purely symptomatic treatments to interventions that address the underlying pathophysiological drivers. Insulin resistance (IR) and the resulting compensatory hyperinsulinemia are recognized as the primary triggers for both metabolic dysfunction and ovarian hyperandrogenism. Our analysis aligns with the findings of Pustotina et al. (2024) and the latest International Evidence-based Guidelines (2023), which emphasize that insulin-sensitizing agents are a cornerstone of therapy. While metformin has historically been the "gold standard" for managing IR, the comparative efficacy of myo-inositol (MI) presented in recent literature, such as the meta-analysis by Fitz et al. (2024) and Gudović et al. (2024), suggests that MI provides equivalent improvements in HOMA-IR and fasting insulin levels. Critically, MI offers a superior safety profile with a total absence of the gastrointestinal side effects (nausea, diarrhea, abdominal pain) that frequently lead to poor compliance or discontinuation of metformin therapy.

4.2. The Ovarian Paradox and the Clinical Significance of AMH

The "Ovarian Paradox" remains a central point of discussion in the current literature regarding PCOS pathophysiology. This phenomenon describes a situation where the ovary remains sensitive to insulin even when peripheral tissues (such as muscle and adipose tissue) exhibit significant resistance. This localized insulin sensitivity, coupled with systemic hyperinsulinemia, triggers an over-activation of the epimerase enzyme in the ovaries, leading to an excessive conversion of myo-inositol (MI) into D-chiro-inositol (DCI). The resulting localized deficiency of MI impairs the follicle's ability to respond to FSH signals, effectively "stalling" oocyte maturation.

Furthermore, the 2023 International Evidence-based Guidelines have introduced pivotal updates regarding the diagnostic framework of PCOS, particularly highlighting the role of Anti-Müllerian Hormone (AMH). While elevated AMH levels have long been associated with the high antral follicle count typical of PCOS, the latest standards recognize AMH as a reliable surrogate marker for polycystic ovarian morphology (PCOM) in adults. In the context of the Ovarian Paradox, pathologically high AMH concentrations often correlate with the severity of

hyperinsulinemia and follicular arrest. Supplementation with myo-inositol has shown promise not only in restoring the MI:DCI balance but also in modulating these endocrine markers, potentially leading to a physiological reduction in AMH levels as ovulatory function is restored. This integration of MI therapy aligns with the modern goal of treating PCOS by addressing both the biochemical markers and the underlying metabolic triggers.

4.3. Optimization of Reproductive Outcomes and Assisted Reproductive Technology

The role of myo-inositol in reproductive medicine extends far beyond cycle regulation. According to the research conducted by Wdowiak (2020) and Zhang et al. (2025), MI supplementation is a critical factor in improving oocyte competence and embryo morphology. MI is highly concentrated in the follicular fluid of healthy follicles, where it plays a vital role in calcium signaling—a process essential for oocyte maturation and successful fertilization. In patients undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI), the administration of MI has been shown to reduce the total dose of exogenous gonadotropins required for stimulation, thereby lowering the risk of Ovarian Hyperstimulation Syndrome (OHSS). This makes MI an indispensable tool for clinicians aiming to increase clinical pregnancy rates while prioritizing patient safety and reducing the economic burden of ART procedures.

4.4. Addressing Inositol Resistance: The Role of Alpha-Lactalbumin in Enhancing Bioavailability

A significant clinical challenge in the treatment of PCOS is the phenomenon of "inositol resistance," which affects approximately 30–40% of the patient population. These individuals fail to achieve therapeutic improvements in metabolic and ovulatory parameters despite standard oral supplementation of myo-inositol. Evidence suggests that this non-responsiveness is primarily rooted in impaired intestinal absorption rather than metabolic cellular resistance. To overcome this barrier, the co-administration of alpha-lactalbumin, a whey-derived protein, has emerged as a transformative solution.

The primary mechanism of action of alpha-lactalbumin lies in its ability to modulate the permeability of the intestinal barrier and the tight junctions of the gut mucosa. By increasing the bioavailability of myo-inositol through improved transepithelial transport, alpha-lactalbumin ensures that effective concentrations of the isomer reach the systemic circulation and the target ovarian tissues. This synergistic approach effectively "rescues" clinical outcomes for non-responders, allowing for the restoration of ovulation and hormonal balance in women

who were previously considered resistant to standard inositol protocols. Consequently, the integration of alpha-lactalbumin represents a major advancement in personalized PCOS therapy, addressing the physiological limitations of absorption that hinder traditional management.

4.5. Pediatric Perspectives and Myo-Inositol as a Metabolic Alternative

The management of PCOS in adolescent patients presents a unique clinical challenge, as traditional interventions like combined oral contraceptives (COCs) often address only the superficial symptoms while potentially masking underlying metabolic dysfunction. Recent evidence emphasizes that myo-inositol (MI) serves as a safe and physiologically appropriate alternative to hormonal birth control in this demographic. Unlike COCs, which may exacerbate insulin resistance in some phenotypes, MI targets the root metabolic drivers by sensitizing tissues to insulin and facilitating the natural maturation of the hypothalamus-pituitary-ovarian axis.

This distinction is of paramount importance for pediatricians and parents who may be concerned about the long-term impact of exogenous steroids on a developing endocrine system. By promoting a spontaneous return to cyclicity and reducing hyperandrogenic manifestations—such as persistent acne and hirsutism—MI offers a high-compliance therapeutic route. Its "Generally Recognized as Safe" (GRAS) status and lack of significant side effects provide a reassurance that is often missing with standard pharmacological agents. Integrating MI into early intervention strategies not only stabilizes current hormonal health but also serves as a preventive measure against the lifelong progression of metabolic comorbidities associated with PCOS.

4.6. Compliance, Longevity of Treatment, and Future Directions

Finally, the long-term success of any PCOS intervention depends on patient adherence. The high level of satisfaction reported in studies involving MI is directly attributed to its "natural" status and lack of toxicity. Unlike many pharmacological interventions, MI is a substance the body recognizes, leading to a high degree of therapeutic compliance. Future research should continue to explore the synergistic effects of MI with other micronutrients, such as Vitamin D and Melatonin, as suggested by Wdowiak, to further refine the management of oxidative stress in the follicular environment. In conclusion, the integration of science-based inositol therapy into standard clinical practice is strongly supported by the current evidence as an effective, safe, and holistic approach to PCOS management.

5. Conclusions

Myo-inositol (MI), particularly when administered in the physiological 40:1 ratio, represents a highly effective and safe therapeutic intervention for managing metabolic and hormonal disruptions in PCOS, offering efficacy comparable to metformin with significantly superior gastrointestinal tolerance. As a key insulin sensitizer, MI directly reduces compensatory hyperinsulinemia and stabilizes glucose metabolism, which is fundamental for the long-term prevention of type 2 diabetes. Utilizing formulations that maintain the 40:1 ratio ensures simultaneous improvement in peripheral insulin sensitivity and restoration of intra-ovarian homeostasis, effectively correcting the "ovarian paradox" and restoring proper FSH signaling within the follicles.

MI supplementation significantly enhances oocyte quality and embryo morphology, leading to improved pregnancy rates in assisted reproductive technology (ART) procedures. By optimizing the follicular fluid environment, this therapy allows for a reduction in exogenous gonadotropin doses and drastically minimizes the risk of Ovarian Hyperstimulation Syndrome (OHSS). In the adolescent population, MI serves as a valuable causal alternative to oral contraceptives, supporting the natural regulation of the hypothalamus-pituitary-ovarian axis during puberty rather than merely masking symptoms, which is crucial for establishing long-term reproductive health.

The incorporation of alpha-lactalbumin represents a breakthrough for "inositol-resistant" patients by modulating intestinal permeability and significantly increasing MI bioavailability, ensuring therapeutic success even in cases of gut dysbiosis. The high safety profile, lack of significant side effects, and positive impact on psychological well-being through serotonergic pathways contribute to excellent patient compliance. The stability of clinical outcomes observed in long-term follow-up studies confirms the validity of including MI as a cornerstone in the standards of comprehensive care for women with PCOS.

Disclosure

Author's contribution

Conceptualization:[AB], [JB]

Methodology: [EC], [AB], [WW]

Check: [KW], [TS], [JN]

Investigation: [EC], [KW], [AB]

Data curation: [JB], [EC], [AB], [KW^2]

Writing - rough preparation: [TS], [WW], [JB]

Writing - review and editing: [KW], [JB]

Visualization: [WW], [EC], [JB]

Project administration: [KW^2] [TS], [JN]

Funding Statement

The article did not receive any funding.

Institutional Review Board Statement

Not Applicable.

Informed Consent Statement

Not Applicable.

Data Availability

Statement Not Applicable.

Acknowledgements

This research has not received any administrative or technical support.

Conflict Of Interest

The authors declare no conflict of interest.

All authors have read and agreed with the published version of the manuscript.

References

1. Akbari Sene, A., Saeedzarandi, M., Moradi, Y., et al. (2025). Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial. *International Journal of Reproductive BioMedicine*, *23*(5). https://doi.org/10.18502/ijrm.v23i5.19260

2. Cantelmi, T., Lambiase, E., Unfer, V. R., Gambioli, R., & Unfer, V. (2021). Inositol treatment for psychological symptoms in Polycystic Ovary Syndrome women. *European Review for Medical and Pharmacological Sciences*, *25*, 2383-2389. https://doi.org/10.26355/eurrev_202103_25409

3. Choudhari, R., Tayade, S., Tiwari, A., & Satone, P. (2024). Diagnosis, Management, and Associated Comorbidities of Polycystic Ovary Syndrome: A Narrative Review. *Cureus*, *16*(4), e58733. https://doi.org/10.7759/cureus.58733

4. Cowan, S., Lim, S., Alycia, C., et al. (2023). Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity. *BMC Endocrine Disorders*, *23*, 14. https://doi.org/10.1186/s12902-022-01208-y

5. Fitz, V., Graca, S., Mahalingaiah, S., et al. (2024). Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. *The Journal of Clinical Endocrinology & Metabolism*, *109*, 1630-1655. https://doi.org/10.1210/clinem/dgad762

6. Lete, I., Martínez, A., Lasaga, I., Centurión, E., & Vesga, A. (2024). Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. *Gynecological Endocrinology*, *40*(1), 2301554. https://doi.org/10.1080/10.1080/09513590.2023.2301554

7. Lentini, G., Querqui, A., Monti, N., & Bizzarri, M. (2024). PCOS and Inositols - Advances and Lessons We are Learning. A Narrative Review. *Drug Design, Development and Therapy*, *18*, 1181–1196. https://doi.org/10.2147/DDDT.S524718

8. Mei, Y., Li, W., Wang, B., et al. (2025). Gut microbiota an emerging target connecting polycystic ovarian syndrome and insulin resistance. *Frontiers in Cellular and Infection Microbiology*, *15*, 1508893. https://doi.org/10.3389/fcimb.2025.1508893

9. Oszukowski, P., Jakimiuk, A., Spaczyński, M., et al. (2022). Position statement of the Expert Group of the Polish Gynecological Society on the use of myo-inositol in patients with polycystic ovary syndrome (PCOS). [Article in Polish].

https://journals.viamedica.pl/ginekologia_polska/article/view/45928/32719

10. Pajtel, K., & Pelczyńska, M. (2019). The use of inositol in the light of the latest scientific research. *Selected Clinical Problems*, 34-40. [Article in Polish]. https://journals.viamedica.pl/forum_leczenia_otylosci/article/view/90249/66957

11. Pustotina, O., Myers, S. H., Unfer, V., & Rasulova, I. (2024). The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. *Gynecologic and Obstetric Investigation*, *89*, 131-139. https://doi.org/10.1159/000536163

12. Radomski, D., & Jarząbek-Bielecka, G. (2019). The myoinositol in the treatment of girls with PCOS - preliminary analysis. *Pediatric Endocrinology*, *18*(1), 37-44. [Article in Polish] https://doi.org/10.18544/EP-01.18.01.1715

13. Roseff, S., & Montenegro, M. (2020). Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. *International Journal of Endocrinology*, 6461254. https://doi.org/10.1155/2020/6461254

14. Sharon, P. M., Mellonie, P., Manivannan, A., Thangaraj, P., & Logeswari, B. M. (2024). The Effectiveness of Myo-Inositol in Women With Polycystic Ovary Syndrome: A Prospective Clinical Study. *Cureus*, *16*(2), e53951. https://doi.org/10.7759/cureus.53951

15. Szkodziak, P., & Paszkowski, T. (2012). The effect of myo-inositol treatment on insulin resistance in patients with polycystic ovary syndrome in a 3-month observation. *e-medycyna.pl*. [Article in Polish]. https://inofem.pl/wp-content/uploads/2022/03/Inofem-Badanie-kliniczne.pdf

16. Teede, H. J., Tay, C. T., Laven, J. J., et al. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. *European Journal of Endocrinology*, *189*, G43-G64. https://doi.org/10.1093/ejendo/lvad096

17. Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. *Endocrine Connections*, *6*, 647-658. https://doi.org/10.1530/EC-17-0243

18. Wdowiak, A., & Filip, M. (2020). The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial. *European Review for Medical and Pharmacological Sciences*, *24*, 8529-8536. https://www.europeanreview.org/wp/wp-content/uploads/8529-8536.pdf

19. Wdowiak, A. (2016). Myoinositol improves embryo development in PCOS patients undergoing ICSI. *International Journal of Endocrinology*, 2016, 6273298. https://doi.org/10.1155/2016/6273298

20. Zhang, J., Zhang, H., Zhou, W., Jiang, M., & Lin, X. (2025). Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis. *Frontiers in Endocrinology*, *16*, 1520362. https://doi.org/10.3389/fendo.2025.1520362

21. Zhao, H., Xing, C., Zhang, J., & He, B. (2021). Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. *Reproductive Health*, *18*, 171. https://doi.org/10.1186/s12978-021-01207-7